期刊文献+

EML4-ALK融合基因与EGFR基因突变在肺腺癌中的表达 被引量:3

Expression of EML4-ALK and EGFR Mutation in Lung Adenocarcinoma
下载PDF
导出
摘要 目的探讨肺腺癌EML4-ALK融合基因与EGFR基因突变的发生率及临床病理特征。方法采用FISH和ARMS方法对安徽省铜陵市人民医院2008~2011年手术切除和经皮肺穿刺活检病理确诊的肺腺癌60例石蜡包埋组织分别进行EML4-ALK融合基因和EGFR基因突变检测,并分析与临床病理特征的相关性。结果肺腺癌病理组织中EML4-ALK融合基因阳性表达率为8.33%,EGFR基因突变率61.67%,女性患者突变率76.92%(20/26)较男性患者突变率50.0%(17/34)高,P=0.034;吸烟<400年支突变率74.29%(26/35)较吸烟≥400支突变率44.0%(11/25)高,P=0.017;≥60岁患者突变率42.86%(12/28)较<60岁患者突变率78.13%(25/32)低,P=0.005,差异均有统计学意义。EML4-ALK和EGFR在肺腺癌患者中表达的相关性分析,显示二者之间呈负相关(R=-0.134,P=0.308),差异无统计学意义。结论 EML4-ALK在肺腺癌中低表达,EGFR基因突变高表达,两者呈负相关。 Objective To investigate the relation between EML4 - ALK fusion gene and EGFR gene positive expression in clinical and pathological characteristics. Methods The study applied FISH and the ARMS technology,with detection of the EML,4 - ALK and EGFR gene in 60 patients from 2008 to 2011 in Tongling People's Hospital with pathologically confirmed lung adenocareinoma cancer tissues. Results In histopathology of lung adenocareinoma,EML4 - ALK fusion gene positive expression rate were 8.33%. The EGFR gene positive expression rate were 61.67%. The mutation rate of 76.92% (20/26)in the female patients was higher compared with male mutation rate of 50.0% (17/34) , and the P values was 0. 034. the mutation rate of patients with smoking 〈 400 years package of[ 74.29% ( 26/35 ) ] was higher compared with smoking≥400 mutation rate[ 44.0% ( 11/25 ) ], and the P values was 0. 017. the mutation rate in the ≥60 - year - old patients[42.86% (12/28) ]was lower compared with 〈60 - year - old mutation rate[78.13% (25/32) ] ,and the P val- ues was 0. 005. All the difference havd statistically significaee. The EMIA -ALK and EGFR of correlation analysis showed correlation( R = - 0. 258,P = 0. 046 〈 0.05 ) ,and the difference was statistical. Conclusion EML4 - ALK positive expression was lower compared with EG- FR. The expression of EGFR and EML4 - ALK showed correlation and the difference had statistical significant.
出处 《医学研究杂志》 2013年第7期109-112,共4页 Journal of Medical Research
基金 铜陵市卫生局科研基金资助项目[(2012)01]
关键词 肺腺癌 EML4-ALK EGFR 荧光原位杂交 Adenocarcinoma lung EML4 - ALK EGFR FISH
  • 相关文献

参考文献9

  • 1吴一龙.Hi,ALK融合基因型肺癌[J].循证医学,2010,10(4):195-197. 被引量:1
  • 2Soda M, Choi YL, Enomoto M yet al. Identification of the transformingEML4-ALK fusion gene in non-small cell lung cancer[ J]. Nature,2007,448(7153):561-566.
  • 3Soda M,Takada S,Takeuchi K,et al. A mouse model for EML4-ALK-positive lung cancer[ J]. Proc Natl Aca Sci USA ,2008 ,105 (50 ):19893-19897.
  • 4Pemer S, Wagner PL, Deraichelis F ,et ai. EML4-ALK fusion lungcancer:a rare acquired event[ J]. Neoplasia,2008 ,10(3):298-302.
  • 5Inamura K, Takeuchi K, Togashi Y, et al, EML4-ALK lung cancersare characterized by rare other mutations,a TTF-1 cell lineage,an aci-nar histology,and young onset[ J]. Mod Pathol,2009,22(4):508-515.
  • 6Wong DW,Leung EL,Kam-Ting K,et al. The EML4-ALK fusiongene is involved in various histologic types of lung cancers fromnonsmokers with wild-type EGFR and K-ras [ J ]. Cancer, 2009,115(8):1723-1733.
  • 7Zhang XC,Zhang S, Yang XN , et al. Fusion of EML4 and ALK isassociated with development of lung adenocarcinomas lacking EGFRand KRAS mutations and is correlated with ALK expression [ J ]. MolCancer,2010,9 : 188.
  • 8冯勤,李向红,陈钊,何京生,王春旭,周立新,薛卫成.非小细胞肺癌表皮生长因子受体基因突变检测及其与临床病理特征的相关性[J].中华病理学杂志,2011,40(10):660-663. 被引量:17
  • 9王芳,付莎,汤涛,邓玲,张晓,李银珍,邵建永.非小细胞肺癌表皮生长因子受体基因突变与临床病理特征的关系[J].中华病理学杂志,2011,40(10):664-666. 被引量:24

二级参考文献35

  • 1Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib[J].N Engl J Med,2004,350(21):2129-2139.
  • 2Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:Correlation with clinical response to Gefitinib therapy[J].Science,2004,304(5676):1497-1500.
  • 3Wu YL,Zhong WZ,Li LY,et al.Epidermal growth factor receptor mutations and their correlation with Gefitinib therapy in patients with non-small cell lung cancer:A meta-analysis based on updated individual patient data from six medical centers in China's Mainland[J].J Thorac Oncol,2007,2(5):430-439.
  • 4Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.
  • 5Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus Cisplatin plus Docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):An open label,randomised phase 3trial[J].Lancet Oncol,201011(2):121-128.(Epub 2009Dec 18.).
  • 6Rosell R,Moran T,Queralt C,et al.Screening for epidermal growth factor receptor mutations in lung cancer[J].N Engl J Med,2009,361(10):958-967.
  • 7Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010,362(25):2380-2388.
  • 8Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(2):561-566.
  • 9Zhang XC,Zhang S,Yang XN,et al.Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression[J].Mol Cancer,2010,9:188.
  • 10Bang Y,Kwak EL,Shaw A,et al.Clinical activity of the oral ALK inhibitor,PF-02341066,in ALK-positive patients with non-small cell lung cancer(NSCLC)[J].J Clin Oncol,2010,28(18s):3.

共引文献33

同被引文献56

  • 1Soda M, Choi YL, Enomoto M, et al. Identification of the transfor- ming EML4-ALK fusion gene in non-small-cell lung cancer [ J ]. Nature, 2007, 448 (7153 ) :561-566.
  • 2Soda M, Takada S, Takeuchi K, et al. A mouse model for EMIA- ALK-positive lung cancer[ J]. Proc Natl Acad Sci USA, 2008, 105 (50) : 19893-19897.
  • 3Mino-Kenudson M, Chirieac L R, Law K, et al. A novel, highly sen- sitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry[ J]. Clin Cancer Res, 2010, 16(5) :1561-1571.
  • 4Zhang X, Zhang S, Yang X, et al. ciated with development of lung ad KRAS mutations and is correlated Cancer, 2010, 9:188.
  • 5Fusion of EMIA and ALK is asso- lacking EGFR and with ALK expression [ J ]. Mol Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event [ J ]. Neoplasia, 2008, 10 (3) : 298- 302.
  • 6Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EMIA- ALKIJ]. J Clin Oncol, 2009, 27(26):4247-4253.
  • 7Takeuehi K, Choi YL, Togashi Y, et al. KIFSB-ALK, a novel fusion oneokinase identified by an immunohistoehemistry-based diagnostic system for ALK-positive lung cancer[ J]. Clin Cancer Res, 2009, 15 (9) :3143-3149.
  • 8Lin E, Li L, Guan Y, et al. Exon array profiling detects EMIA-ALK fusion in breast, colorectal, and non-small cell lung cancers[ J]. Mol Cancer Res, 2009, 7(9) :1466-1476.
  • 9Tuononen K, Sarhadi VK, Wirtanen A, et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR : A comparison of four methods[ J]. Biomed Res Int, 2013, 2013:757490.
  • 10Inamura K, Takeuchi K, Togashi Y, et al. EMIA-ALK fusion is linked to histological characteristics in a subset of lung cancers[ J]. J Thoracic Oncol, 2008, 3(1) : 13-17.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部